Friday, 13 Jul 2018

You are here

The RheumNow Week in Review – 24 February 2017

Dr. Jack Cush reviews highlights from the past week on

  1. Study of >43K Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis patients show a 14-34% increase risk for depression; but not for suicide or suicidal ideation.
  2. Scleroderma Renal Crisis Criteria include HTN, Acute Kidney Injury, encephalopathy, seizures, microangiopathic hemolytic anemia
  3. 183 SLE Patients in a Phase II trial showed no benefit with IL-6 inhibition(PF-04236921) for 6 mos. The highest dose was D/C for safety.
  4. #RWCS17 Dr Bergman shows incredibly poor adherence to drug therapy. Suggests you need time and a plan to combat
  5. Analysis 26 studies failed to show any predictors of mycohenolate mofetil responses in Lupus. More research needed.
  6. Metanalysis shows no Cancer risk with Inflx (OR 1.68), ETN (0.79), ADA (0.93), ABA (1.04), RTX (0.58), TCZ (0.60), Tofa (1.15)
  7. Prior Authorizations is a problem for GI docs too - 63% use >25% FTE to do PA and 73% make > 5 calls (37% >10 calls) per day to payors
  8. CDC reports seasonal Influenza peaked in 2nd week Feb 2017 & will continue for weeks. No antiviral resistance seen thus far.
  9. Dr Mahadevan #RWCS17 shows data that there is a 1/2000 risk of bone fractures with chronic PPI use
  10. Dr Mahadevan #RWCS17 shows that PPI chronic use yields a 1/4000 risk of PPI induced C. ridicule diarrhea
  11. #rwcs2017 Dr Kavanaugh shows RCT where apemilast does well against etanercept in psoriasis.
  12. Dr Kevin Winthrop at #RWCS2017 reviews DMARD/Biologic effects on vaccine responses. Most effected by RTX, least by MTX.
  13. ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos
  14. FDA approves the IL-17 inhibitor “Siliq” (brodalumab; from Valeant) for moderate-severe plaque psoriasis.Comes with a black box warning for suicide.
  15. Baricitinib (trade name “Olumiant” ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo with MTX.
  16. Higher Hip and Knee Replacement Revision Rates in Younger Patients 
  17. Sirukumab shows moderate efficacy in Rheumatoid Arthritis
  18. Abatacept shows modest efficacy in Giant Cell Arteritis
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)

Dr. Jack Cush reviews the news and journal articles from the past week on  Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Dr. Jack Cush reviews selected news and journal reports from the past week on

The RheumNow Week in Review – EULAR18 Epilogue (6.22.18)

Dr. Jack Cush reviews EULAR 2018 and the past week's news and reports from, including DMARDs in OA, the price of Penicillamine, Infections when ANCA+, CV outcomes in gout, NSAIDs in Pregnancy and Seropostive vs. Seronegative Outcomes.

CDC Obesity Prevalence Higher in the Rural USA

MMWR reports that approximately 46 million persons (14%) in the United States live in nonmetropolitan counties, where there is a higher prevalence of obesity-associated chronic diseases such as diabetes, coronary heart disease, and arthritis. (Citation source:

EULAR 2018 - Podcast from Day 4

This EULAR 2018 Podcast is a compilation of audio clips from EULAR in Amsterdam.

Click HERE to listen.

You can also listen on iTunes, Soundcloud or Stitcher.